Skip to main content
Top
Published in: Endocrine 2/2009

01-04-2009 | Case Report

VIPoma with expression of both VIP and VPAC1 receptors in a patient with WDHA syndrome

Authors: Shoko Nakayama, Taiji Yokote, Kichinosuke Kobayashi, Yuji Hirata, Tetsuya Hiraiwa, Izumi Komoto, Kazuho Miyakoshi, Yoshiko Yamakawa, Takayuki Takubo, Motomu Tsuji, Masayuki Imamura, Toshiaki Hanafusa

Published in: Endocrine | Issue 2/2009

Login to get access

Abstract

We report a case of VIPoma in a 72-year-old female patient who presented with excessive diarrhea, severe hypokalemia, and acidemia. She had been referred to our hospital three times because of severe diarrhea. No primary tumor site was found by conventional techniques, including contrast-enhanced CT and MRI, angiography, endoscopy, and positron emission tomography (PET), but a tumor was subsequently found in the head of the pancreas by octreotide scanning. Her diarrhea diminished dramatically after octreotide treatment, while her diarrhea has ceased without the therapy of octreotide at the first admission in the course of 2 years of her disease. Immunohistochemial analysis of the excised tumor tissue revealed the expression of both vasoactive intestinal peptide (VIP) and VIP and pituitary adenylate cyclase-activating peptide 1 (VPAC1) receptors. This is the first case report of a VIPoma that immunostains for VIP and VPAC1 receptors and indicates that abundant VIP produced by VIPoma might inhibit its growth and reduce VIP secretion via the VPAC1 receptor in vivo.
Literature
1.
go back to reference I.M. Modlin, J.J. Lewis, H. Ahlmann et al., Surg. Gynecol. Obstet. 176, 507–518 (1993)PubMed I.M. Modlin, J.J. Lewis, H. Ahlmann et al., Surg. Gynecol. Obstet. 176, 507–518 (1993)PubMed
4.
go back to reference C. Capella, J.M. Polak, R. Buffa, F.J. Tapia, P. Heitz, L. Usellini et al., Cancer 52, 1860–1874 (1983)CrossRefPubMed C. Capella, J.M. Polak, R. Buffa, F.J. Tapia, P. Heitz, L. Usellini et al., Cancer 52, 1860–1874 (1983)CrossRefPubMed
10.
go back to reference M. Laburthe, A. Couvineau, B. Amiranoff, T. Voisin, Bailleres Clin. Endocrinol. Metab. 8, 77–110 (1994)CrossRef M. Laburthe, A. Couvineau, B. Amiranoff, T. Voisin, Bailleres Clin. Endocrinol. Metab. 8, 77–110 (1994)CrossRef
11.
go back to reference M. Laburthe, A. Couvineau, J.C. Marie, VPAC receptors for VIP and PACAP. Recept. Channels 8, 137–153 (2002)CrossRefPubMed M. Laburthe, A. Couvineau, J.C. Marie, VPAC receptors for VIP and PACAP. Recept. Channels 8, 137–153 (2002)CrossRefPubMed
12.
go back to reference S.W. Kim, R.D. Beauchamp, C.M. Townsend Jr, J.C. Thompson, Surgery 110, 270–276 (1991)PubMed S.W. Kim, R.D. Beauchamp, C.M. Townsend Jr, J.C. Thompson, Surgery 110, 270–276 (1991)PubMed
14.
go back to reference I. Virgolini, Q. Yang, S. Li, P. Angelberger, N. Neuhold, B. Niederle et al., Cancer Res. 54, 690–700 (1994)PubMed I. Virgolini, Q. Yang, S. Li, P. Angelberger, N. Neuhold, B. Niederle et al., Cancer Res. 54, 690–700 (1994)PubMed
16.
17.
go back to reference L. Gemet, J.C. Murat, C. Remaury, P. Valet, H. Paris, C. Denis-Pouxviel, J. Cell Pathol. 150, 501–509 (1992) L. Gemet, J.C. Murat, C. Remaury, P. Valet, H. Paris, C. Denis-Pouxviel, J. Cell Pathol. 150, 501–509 (1992)
18.
go back to reference S.P. Sreedharan, D.R. Patel, M. Xia, S. Ichikawa, E.J. Goetzl, Biochem. Biophs. Res. Commun. 203, 141–148 (1994)CrossRef S.P. Sreedharan, D.R. Patel, M. Xia, S. Ichikawa, E.J. Goetzl, Biochem. Biophs. Res. Commun. 203, 141–148 (1994)CrossRef
19.
go back to reference P. Tagliaferri, D. Katsares, T. Clair, S. Ally et al., Cancer Res. 48, 1642–1650 (1988)PubMed P. Tagliaferri, D. Katsares, T. Clair, S. Ally et al., Cancer Res. 48, 1642–1650 (1988)PubMed
Metadata
Title
VIPoma with expression of both VIP and VPAC1 receptors in a patient with WDHA syndrome
Authors
Shoko Nakayama
Taiji Yokote
Kichinosuke Kobayashi
Yuji Hirata
Tetsuya Hiraiwa
Izumi Komoto
Kazuho Miyakoshi
Yoshiko Yamakawa
Takayuki Takubo
Motomu Tsuji
Masayuki Imamura
Toshiaki Hanafusa
Publication date
01-04-2009
Publisher
Springer US
Published in
Endocrine / Issue 2/2009
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-009-9146-6

Other articles of this Issue 2/2009

Endocrine 2/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine